NCT02289950 - A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer | Biotech Hunter

Enrollment

332

Participants

Timeline

Start Date

March 19, 2015

Primary Completion Date

May 31, 2019

Study Completion Date

August 13, 2020

Conditions

Platinum-Sensitive Ovarian Cancer in First Relapse

Interventions

DRUG

Farletuzumab

Farletuzumab will be administered intravenously (IV) weekly

DRUG

Placebo

Placebo will be administered intravenously (IV) weekly

Trial Locations (68)

Unknown

Phoenix

Los Angeles

Orange

Roseville

Sacramento

Aurora

Miami

Miramar

Orlando

Sarasota

Tampa

Atlanta

Augusta

Savannah

Chicago

Lexington

Louisville

Baltimore

Boston

Detroit

Minneapolis

Grand Island

New York

Chapel Hill

Charlotte

Winston-Salem

Centerville

Cincinnati

Cleveland

Columbus

Chattanooga

Knoxville

Austin

Annandale

Charlottesville

Edegem

Brussels

Hasselt

Ghent

Leuven

Liège

Ulm

Chemnitz

Berlin

Dresden

Essen

Bari

Napoli

Rome

Avellino

Bologna

Milan

Napoli

Perugia

Chūōku

Hidaka

Kashiwa

Kōtoku

Kurume

Matsuyama

Minatoku

SuntoGun

Palma de Mallorca

Córdoba

Madrid

Sabadell

Plymouth

London

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY